Investigating new compounds to protect brain cells in Parkinson's disease using zebrafish models
Official title: In vitro pharmacology and In vivo neuroprotective effects of CMPI analogues in an optimized Zebrafish model of Parkinsons disease
Funded at University of Texas Tyler · NIH-11082980 · Data updated 2026-11-12
This study is looking for new medications that could help protect brain cells in people with Parkinson's disease by testing a special compound in zebrafish to see if it can keep important brain cells healthy and slow down the disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Tyler NIH-funded |
| Lab location | 1 site (Tyler, United States) |
| Project start | May 20, 2022 |
| Project end | April 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $147,000 |
| NIH project number | 5R16NS129676-04 |
| Project ID | NIH-11082980 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Parkinson's disease who are experiencing a decline in their motor functions.
✕Less likely to help
Patients with Parkinson's disease who are in advanced stages and have significant neurodegeneration may not benefit from this research.
What this research studies
This research focuses on developing new drugs that can protect brain cells in patients with Parkinson's disease (PD). It aims to create and test analogs of a compound called CMPI, which may enhance the function of certain receptors in the brain that are important for neuroprotection and reducing inflammation. By using zebrafish models, the researchers will evaluate how effective these compounds are in preventing the loss of dopaminergic neurons, which are crucial for movement and coordination. The goal is to find treatments that not only alleviate symptoms but also modify the disease's progression.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that slow down or even halt the progression of Parkinson's disease.
How similar studies have gone: Other research has shown promise in developing neuroprotective agents for Parkinson's disease, but this specific approach using CMPI analogs is relatively novel.
Where this research is happening
-
University of Texas Tyler
Tyler, United States Active
Researchers
- Principal investigator: Hamouda, Ayman K. — University of Texas Tyler
- Study coordinator: Hamouda, Ayman K.
Related research
Other NIH-funded projects on the same topics.
-
Gut-brain clues in Parkinson’s disease: supplement to a large registry
A plant-wide supplement to an NIH program will enroll people with Parkinson’s, with and without GI symptoms, plus healthy controls, to study how gut function, brain signals, and sleep rhythms relate to Parkinson’s symptoms.
-
Gut-brain connections in Parkinson’s disease: how the gut and environment shape symptoms
A Mayo Clinic team is studying how gut problems, environmental factors, and genetics together influence Parkinson’s disease and its GI symptoms to find biomarkers and better understanding of the disease.
-
Gut-brain communication in Parkinson’s disease for better symptoms and daily life
This project enrolls people with Parkinson’s disease and healthy controls to build a big registry and study how gut function, brain signals, sleep, and circadian rhythms relate to PD symptoms.
-
Gut microbiome and Parkinson's disease: how gut bugs relate to symptoms and progression
A multi-year study will look at gut bacteria and related markers in people with Parkinson’s disease to understand how the gut-brain connection may influence symptoms and progression.
-
Gut-Brain Axis in Parkinson’s Disease: biomarkers and procedures to track progression
A patient-focused program to study how gut health and the brain interact in Parkinson’s disease using biomarkers and clinical procedures.
-
How air pollution, weather, and green spaces affect Parkinson’s symptoms in older adults
This project looks at whether everyday environmental factors like air quality, temperature, and access to parks worsen or improve Parkinson’s symptoms in people aged 65 and up.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.